NVIDIA
NVDA
Tesla
TSLA
Super Micro Computer
SMCI
4
Palantir
PLTR
5
Hims & Hers Health
HIMS
US Stock MarketDetailed Quotes
STTK Shattuck Labs
- 1.910
- +0.190+11.05%
Close Feb 25 16:00 ET
- 1.890
- -0.020-1.05%
Pre 05:05 ET
91.18MMarket Cap-1.25P/E (TTM)
1.940High1.460Low565.03KVolume1.600Open1.720Pre Close954.76KTurnover2.35%Turnover RatioLossP/E (Static)47.74MShares11.76052wk High0.94P/B45.87MFloat Cap0.94052wk Low--Dividend TTM24.02MShs Float60.516Historical High--Div YieldTTM27.91%Amplitude0.940Historical Low1.689Avg Price1Lot Size
Shattuck Labs Stock Forum
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
Thursday, 20th February at 9:00 am
– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxicology study –
– SL-325 receptor occu...
Abstract accepted for poster presentation at the upcoming Crohn's and Colitis Congress, to be held February 6–8, 2025 in San Francisco, CA.Abstract accepted for oral presentation at the upcoming20th European Crohn's and Colitis Organization Congress, to be held February 19–22, 2025 in Berlin, Germany.
Upcoming Investor Conference Pre...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
Shattuck Labs (Nasdaq: STTK) announced a strategic pipeline prioritization, discontinuing its SL-172154 clinical program due to modest improvements in overall survival for TP53 mutant AML and HR-MDS patients. The company will focus on SL-325, a first-in-class DR3 antagonist antibody for inflammatory bowel disease (IBD...
Benzinga
The company observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had no...
No comment yet